Vor Biopharma Stock Soars 123.83% on Funding, Licensing Deal

On June 26, 2025, Vor Biopharma's stock surged by 123.83% in pre-market trading, marking a significant milestone for the biopharmaceutical company.

Vor Biopharma recently announced a $175 million private placement, intending to use the net proceeds to advance its clinical pipeline and for general corporate purposes. This funding is expected to bolster the company's development efforts and strategic initiatives.

The company has also entered into an exclusive global license agreement with RemeGen for a late-stage autoimmune asset. This agreement includes an initial payment of $125 million, with potential future milestones exceeding $4 billion. The deal underscores Vor Biopharma's commitment to expanding its portfolio and enhancing its market position.

Additionally, Vor Biopharma has announced changes to its board of directors, effective June 25, 2025. These changes are part of the company's ongoing efforts to strengthen its leadership and governance structure, ensuring it is well-positioned to navigate the dynamic biopharmaceutical landscape.